Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
MLTX Stock Chart & Stats
$14.34
-$0.83(-1.65%)
At close: 4:00 PM EST
$14.34
-$0.83(-1.65%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume45.38K
Average Volume (3M)1.48M
Market Cap
$805.81M
Enterprise Value$151.89M
Total Cash (Recent Filing)$380.48M
Total Debt (Recent Filing)$75.73M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Feb 26, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding70,847,404
10 Day Avg. Volume1,181,192
30 Day Avg. Volume1,476,025
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)7.62
Price to Sales (P/S)0.00
P/FCF Ratio-29.07
Enterprise Value/Market Cap0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-102.15
Enterprise Value/Ebitda-0.73
Forecast
1Y Price Target
$24.10Price Target Upside68.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationClinical data suggest sonelokimab's nanobody design and dual targeting of IL‑17A and IL‑17F could provide differentiated efficacy and a more favorable tolerability profile versus current IL‑17A therapies, aiding competitive positioning if confirmed in late‑stage readouts.
Financial RunwayRecent equity financing alongside non‑dilutive funding supports MoonLake's cash position and should extend operational runway into 2028, reducing near‑term capital risk for advancing key programs.
Regulatory PathwayFDA feedback indicates existing pivotal and supportive trial results may be sufficient to support a biologics license application for sonelokimab in hidradenitis suppurativa, reducing the need for an additional pivotal trial and lowering regulatory uncertainty.
Bears Say
Market OpportunityRecent trial outcomes suggest the addressable market for sonelokimab in the skin disease may be smaller than earlier estimates, which could constrain peak sales potential.
Reimbursement And Adoption HeadwindsComplicated payer coverage dynamics for a new therapy could slow adoption of sonelokimab and limit market penetration even if regulatory approval is achieved.
Valuation And Dilution RiskAnalyst revisions citing equity dilution and higher projected operating expenses signal potential downward pressure on valuation and investor sentiment.
MoonLake Immunotherapeutics News
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $805.81M.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 47 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Nov 05, 2025. The company reported -$1.1 earnings per share for the quarter, missing the consensus estimate of -$0.879 by -$0.221.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.99.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 70,847,404 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$1.1 in its last earnings report, missing expectations of -$0.879. Following the earnings report the stock price went up 4.541%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MoonLake Immunotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.10 (68.06% Upside)
$24.10 (68.06% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 249.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.23%
12-Months-Change
Fundamentals
Return on Equity
-54.17%
Trailing 12-Months
Asset Growth
-20.05%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$24.10
▲(68.06% Upside)
Technical Analysis
Protagonist Therapeutics
―
Zai Lab
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
―
Ownership Overview
40.00% Insiders
11.48% Mutual Funds
41.83% Other Institutional Investors
6.13% Public Companies and Individual Investors